Effects of Hormones

  • Michael T. Mazur
  • Robert J. Kurman


Women receive hormone preparations for a variety of reasons, including birth control, dysfunctional uterine bleeding, perimenopausal and postmenopausal symptoms, endometriosis, endometrial hyperplasia and carcinoma, breast carcinoma, and certain types of infertility. Usually the exogenous hormone is some form of progestin, but estrogenic and even androgenic hormones are used for some disorders. The endometrium shows the effects of these hormones.


Luteinizing Hormone Oral Contraceptive Obstet Gynecol Medroxyprogesterone Acetate Endometrial Polyp 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Speroff L, Glass RH, Kase NG: Clinical Gynecologic Endocrinology and Infertility. 4th ed. Baltimore: Williams & Wilkins, 1989.Google Scholar
  2. 2.
    Schiff I: Menopause. In: Gynecology: Principles and Practice. Kistner RW, ed. Chicago: Year Book Medical Publishers, 1986;565–582.Google Scholar
  3. 3.
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–1037.PubMedGoogle Scholar
  4. 4.
    Whitehead MI, Fraser D: The effects of estrogens and progestogens on the endometrium. Obstet Gynecol Clin North Am 1987;14:299–320.PubMedGoogle Scholar
  5. 5.
    Ober W: Effects of oral and intrauterine administration of contraceptives on the uterus. Hum Pathol 1977;8:513–527.PubMedCrossRefGoogle Scholar
  6. 6.
    Dallenbach-Hellweg G: Histopathology of the Endometrium. 4th ed. New York: Springer-Verlag, 1987.CrossRefGoogle Scholar
  7. 7.
    Kurman RJ, Mazur MT: Benign diseases of the endometrium. In: Blaustein’s Pathology of the Female Genital Tract. 4th ed. Kurman RJ, ed. New York: Springer-Verlag, 1994;367–409.CrossRefGoogle Scholar
  8. 8.
    Hendrickson MR, Kempson RL: Surgical Pathology of the Uterine Corpus (Major Problems in Pathology series). Volume 12. Philadelphia: W.B. Saunders, 1980.Google Scholar
  9. 9.
    Deligdisch L: Effects of hormone therapy on the endometrium. Mod Pathol 1993;6:94–106.PubMedGoogle Scholar
  10. 10.
    Hesla, J. Kurman R, Rock J: Histologic effects of oral contraceptives on the uterine corpus and cervix. Semin Reprod Endocrinol 1989:7:213–219.CrossRefGoogle Scholar
  11. 10a.
    Moyer DL, deLignieres B, Driguez P, Pez JP: Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: Influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992–997.PubMedGoogle Scholar
  12. 11.
    Dockerty MB, Smith RA, Symmonds RE: Pseudo-malignant endometrial changes induced by administration of new synthetic progestins. Staff Meetings of the Mayo Clinic 1959;34:321–328.Google Scholar
  13. 12.
    Cruz-Aquino M, Shenker L, Blaustein A: Pseudo-sarcoma of the endometrium. Obstet Gynecol 1967;29:93–96.PubMedGoogle Scholar
  14. 13.
    Clement PB, Scully RE: Idiopathic postmenopausal decidual reaction of the endometrium. Int J Gynecol Pathol 1988;7:152–161.PubMedCrossRefGoogle Scholar
  15. 13a.
    Iezzoni JC, Mills SE: Predecidualized signet-ring stromal cells mimicking adenocarcinoma in endometrial biopsy specimens. Mod Pathol 1994;70: 90A (abstract).Google Scholar
  16. 14.
    Bernardini L, Araujo FE, Balmaceda JP: A case of permanent endometrial hypotrophy after long-term use of oral contraceptives. Hum Reprod 1993;8:543–546.PubMedGoogle Scholar
  17. 15.
    Gelfand MM, Ferenczy A: A prospective 1-year study of estrogen and progestin in postmenopausal women: Effects on the endometrium. Obstet Gynecol 1989;74:398–402.PubMedGoogle Scholar
  18. 16.
    Mishell DR, Jr: Menopause. In: Comprehensive Gynecology. Herbst AL, Mishell DR, Jr, Sten-chever MA, Droegemueller W, eds. St. Louis: Mosby Year Book, 1992; 1245–1280.Google Scholar
  19. 17.
    Byrjalsen I, Thormann L, Meinecke B, Riis BJ, Christiansen C: Sequential estrogen and progestogen therapy—Assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol 1992;79:523–528.PubMedGoogle Scholar
  20. 18.
    Magos AL, Brewster E, Singh R, O’Dowd T, Brincai M: Amenorrhea and endometrial atrophy with continuous oral estrogens and progestogen therapy in post-menopausal women. Obstet Gynecol 1985;65:496–499.PubMedGoogle Scholar
  21. 19.
    Hillard TC, Siddle NC, Whitehead MI, Fraser DI, Pryse-Davies J: Continuous combined conjugated equine estrogen-progestogen therapy—effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167:1–7.PubMedGoogle Scholar
  22. 20.
    Te Linde RW, Henriksen E: Decidualike changes in the endometrium without pregnancy. Am J Obstet Gynecol 1940;39:733–749.Google Scholar
  23. 21.
    Dallenbach-Hellweg G, Hohagen F: On the problem of premature decidualization induced by the embryo transfer. Lab Invest 1985;52: 17A. (Abstract)Google Scholar
  24. 22.
    Tamada T, Okagaki T, Maruyama M, Matsumoto S: Endometrial histology associated with an intrauterine contraceptive device. Am J Obstet Gynecol 1967;98:811–817.PubMedGoogle Scholar
  25. 23.
    Bonney WA, Glasser SR, Clewe TH, Noyes RW, Cooper CL: Endometrial response to the intrauterine device. Am J Obstet Gynecol 1966;96: 101–113.PubMedGoogle Scholar
  26. 24.
    Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013–1017.PubMedCrossRefGoogle Scholar
  27. 25.
    Segna RA, Dottino RR, Deligdisch L, Cohen CJ: Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416–418.PubMedGoogle Scholar
  28. 26.
    Magriples U, Naftolin F, Schwartz PE, Carcangiu ML: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485–490.PubMedGoogle Scholar
  29. 27.
    Gusberg SB: Tamoxifen for breast cancer: Associated endometrial cancer. Cancer 1990;65: 1463–1464.PubMedCrossRefGoogle Scholar
  30. 28.
    Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;1:117–120.PubMedCrossRefGoogle Scholar
  31. 29.
    Seoud MF, Johns J, Weed JC, Jr: Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165–169.PubMedGoogle Scholar
  32. 29a.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, J Natl Cancer Inst 1994;86:527–537.PubMedCrossRefGoogle Scholar
  33. 30.
    Nuovo MA, Nuovo GJ, McCaffrey FM, Levine RU, Barron B, et al: Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125–131.PubMedCrossRefGoogle Scholar
  34. 31.
    Corley D, Rowe J, Curtis MT, Hogan WM, Noum-off JS, et al: Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992;79:111–116.PubMedGoogle Scholar
  35. 32.
    Cohen I, Shapira J, Altaras M, Cordoba M, Rosen D, et al: Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. Br J Obstet Gynaecol 1992; 99:773–774.PubMedCrossRefGoogle Scholar
  36. 33.
    Lahti E, Blanco G, Kauppila A, Apajasarkkinen M, Taskinen PJ, et al: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660–664.PubMedGoogle Scholar
  37. 34.
    Wentz AC: Endometrial biopsy in the evaluation of infertility. Fertil Steril 1980;33:121–124.PubMedGoogle Scholar
  38. 35.
    Keenan JA, Herbert CM, Bush JR, Wentz AC: Diagnosis and management of out-of-phase endometrial biopsies among patients receiving clomi-phene citrate for ovulation induction. Fertil Steril 1989;51:964–967.PubMedGoogle Scholar
  39. 36.
    Cook CL, Schroeder JA, Yussman MA, Sanfilippo JS: Induction of luteal phase defect with clomi-phene citrate. Am J Obstet Gynecol 1984; 149: 613–616.PubMedGoogle Scholar
  40. 37.
    Van Hall EV, Mastboom JL: Luteal phase insufficiency in patients treated with clomiphene. Am J Obstet Gynecol 1969;103:165–171.PubMedGoogle Scholar
  41. 38.
    Yeko TR, Bardawil WA, Nicosia SM, Dawood MY, Maroulis GB: Histology of midluteal corpus luteum and endometrium from clomiphene citrate-induced cycles. Fertil Steril 1992;57:28–32.PubMedGoogle Scholar
  42. 39.
    Hecht BR, Bardawil WA, Khan-Dawood FS, Dawood MY: Luteal insufficiency: Correlation between endometrial dating and integrated progesterone output in clomiphene citrate-induced cycles. Am J Obstet Gynecol 1990; 163:1986–1991.PubMedGoogle Scholar
  43. 40.
    Lamb EJ, Colliflower WW, Williams JW: Endometrial histology and conception rates after clomiphene citrate. Obstet Gynecol 1972;39:389–396.PubMedGoogle Scholar
  44. 41.
    Benda JA: Glomiphene’s effect on endometrium in infertility. In J Gynecol Pathol 1992; 11:273–282.CrossRefGoogle Scholar
  45. 42.
    Birkenfeld A, Navot D, Levij IS, Laufer N, Beier-Hellwig K, et al: Advanced secretory changes in the proliferative human endometrial epithelium following clomiphene citrate treatment. Fertil Steril 1986;45:462–468.PubMedGoogle Scholar
  46. 43.
    Thatcher SS, Donachie KM, Glasier A, Hillier SG, Baird DT: The effects of clomiphene citrate on the histology of human endometrium in regularly cycling women undergoing in vitro fertilization. Fertil Steril 1988;49:296–301.PubMedGoogle Scholar
  47. 44.
    Li TC, Warren MA, Murphy C, Sargeant S, Cooke ID: A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol 1992;99:1008–1013.PubMedCrossRefGoogle Scholar
  48. 45.
    Floyd WS: Danazol: Endocrine and endometrial effects. IntJ Fertil 1980;25:75–80.Google Scholar
  49. 46.
    Fedele L, Marchini M, Bianchi S, Baglioni A, Bocciolone L, et al: Endometrial patterns during danazol and buserelin therapy for endometriosis: Comparative structural and ultrastructural study. Obstet Gynecol 1990:76:79–84.PubMedGoogle Scholar
  50. 47.
    Soh E, Sato K: Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer 1990;66:983–988.PubMedCrossRefGoogle Scholar
  51. 48.
    Wentz AC, Jones GS, Sapp KC, King TM: Progestational activity of danazol in the human female subject. Am J Obstet Gynecol 1976; 126:378–384.PubMedGoogle Scholar
  52. 49.
    Marchini M, Fedele L, Bianchi S, Dinola G, Nava S, et al: Endometrial patterns during therapy with danazol or gestrinone for endometriosis—Structural and ultrastructural study. Hum Pathol 1992;23:51–56.PubMedCrossRefGoogle Scholar
  53. 50.
    Jeppsson S, Mellquist P, Rannevik G: Short-term effects of danazol on endometrial histology. Acta Obstet Gynecol Scand Suppl 1984;123:41–44.PubMedCrossRefGoogle Scholar
  54. 51.
    Brooks PG, Serden SP, Davos I: Hormonal inhibition of the endometrium for resectoscopic endometrial ablation. Am J Obstet Gynecol 1991; 164:1601–1608.PubMedGoogle Scholar
  55. 52.
    Reshef E, Segars JH, Hill GA, Pridham DD, Yussman MA, et al: Endometrial inadequacy after treatment with human menopausal gonadotropin/human chorionic gonadotropin. Fertil Steril 1990;54:1012–1016.PubMedGoogle Scholar
  56. 53.
    Bonhoff A, Naether O, Johannisson E, Bohnet HG: Morphometric characteristics of endometrial biopsies after different types of ovarian stimulation for infertility treatment. Fertil Steril 1993;59:560–566.PubMedGoogle Scholar
  57. 54.
    Campbell BF, Phipps WR, Nagel TC: Endometrial biopsies during treatment with subcutaneous pulsatile gonadotropin releasing hormone and luteal phase human chorinonic gonadotropins. Int J Fertil 1988;33:329.PubMedGoogle Scholar
  58. 55.
    Sterzik K, Dallenbach C, Schneider V, Sasse V, Dallenbach-Hellweg G: In vitro fertilization: The degree of endometrial insufficiency varies with the type of ovarian stimulation. Fertil Steril 1988;50: 457–462.PubMedGoogle Scholar
  59. 56.
    Garcia JE, Acosta AA, Hsiu J-G, Jones HW, Jr: Advanced endometrial maturation after ovulation induction with human menopausal gonado-tropin/human chorionic gonadotropin for in vitro fertilization. Fertil Steril 1984;41:31–35.PubMedGoogle Scholar
  60. 57.
    Sharma V, Whitehead M, Mason B, Pryse-Davies J, Ryder T, et al: Influence of superovulation on endometrial and embryonic development. Fertil Steril 1990;53:822–829.PubMedGoogle Scholar
  61. 57a.
    Benadiva CA, Metzger DA: Superovulation with human menopausal gonadotropins is associated with endometrial gland-stroma dyssynchrony. Fertil Steril 1994;61:700–704.PubMedGoogle Scholar
  62. 57b.
    Macrow PJ, Li T-C, Seif MW, Buckley CH, El-stein M: Endometrial structure after superovula-tion: A prospective controlled study. Fertil Steril 1994;61:696–699.PubMedGoogle Scholar
  63. 58.
    Casper RF: Clinical uses of gonadotropin-releas-ing hormone analogues. Can Med Assoc J 1991; 144:153–158.Google Scholar
  64. 59.
    Lemay A, Jean C, Faure N: Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach. Fertil Steril 1987;48:775–782.PubMedGoogle Scholar
  65. 60.
    Spitz IM, Bardin CW: Mifepristone (RU 486)—A modulator of progestin and glucocorticoid action. N Engl J Med 1993;329:404–412.PubMedCrossRefGoogle Scholar
  66. 61.
    Swahn ML, Bygdeman M, Cekan S, Xing S, Masironi B, et al: The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod 1990;5:402–408.PubMedGoogle Scholar
  67. 62.
    Li T-G, Dockery P, Thomas P, Rogers AW, Lenton EA, et al: The effects of progesterone receptor blockade in the luteal phase of normal fertile women. Fertil Steril 1988;50:732–742.PubMedGoogle Scholar
  68. 63.
    Batista MC, Gartledge TP, Zellmer AW, Merino MJ, Axiotis C, et al: Delayed endometrial maturation induced by daily administration of the anti-progestin RU-486—A potential new contraceptive strategy. Am J Obstet Gynecol 1992; 167: 60–65.PubMedGoogle Scholar
  69. 64.
    Koering MJ, Healy DL, Hodgen GD: Morphologic response of endometrium to a progesterone receptor antagonist, RU486, in monkeys. Fertil Steril 1986;45:280–287.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Michael T. Mazur
    • 1
  • Robert J. Kurman
    • 2
    • 3
  1. 1.Crouse Irving Memorial Hospital, Health Science CenterState University of New YorkSyracuseUSA
  2. 2.Departments of Gynecology and Obstetrics and PathologyThe Johns Hopkins HospitalBaltimoreUSA
  3. 3.The Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations